Stay updated on Avelumab in 3rd-Line Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the treatment with avelumab plus best supportive care versus physician's choice plus best supportive care for unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:40.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.'
    Difference
    23%
    Check dated 2024-05-22T21:02:37.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:39:51.000Z thumbnail image

Stay in the know with updates to Avelumab in 3rd-Line Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page.